Descriptive analysis of the efficacity of R-GEMOX /R-IE/R-CEPP in patients with relapsed/refractory (R/R) transplant-ineligible diffuse large B-cell lymphoma (DLBCL)
All three regimens show modest survival benefit especially between last anticancer treatment course and death. Emergence of bispecific antibodies and Cart-cells for which real-life benefits have yet to be demonstrated could be coupled with improved access to early palliative care.
Authors
- T. K. Chow Vincent
- Florian Slimano (ORCID: https://orcid.org/0000-0001-5139-7034)
- Éric Durot (ORCID: https://orcid.org/0000-0003-3463-0089)
- Baptiste Fulbert (ORCID: https://orcid.org/0009-0009-2754-5557)
- Justine Clarenne (ORCID: https://orcid.org/0000-0001-8400-2174)
- Antoine Le Bozec (ORCID: https://orcid.org/0000-0002-0789-5180)
- Imman Abdelouahab
Institutions
- Inserm (FR)
- Université Paris-Saclay (FR)
- Centre Hospitalier Universitaire de Reims (FR)
- BioSpectroscopie Translationnelle
- Biomatériaux et Inflammation en Site Osseux (FR)
- Université de Reims Champagne-Ardenne (FR)
Publication Details
- Journal
- Journal of Oncology Pharmacy Practice
- Published
- 2025-02-03
- DOI
- https://doi.org/10.1177/10781552241313381
- Citations
- 1
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.05